Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor for Tumor Angiogenesis Research

Executive Summary: Anlotinib hydrochloride (APExBIO, SKU C8688) is a nanomolar multi-target tyrosine kinase inhibitor that blocks VEGFR2, PDGFRβ, and FGFR1, directly suppressing angiogenesis in preclinical models (product) [1]. It demonstrates rapid oral absorption, high plasma protein binding (93% in humans), and tissue accumulation, including the lung, liver, kidney, heart, and tumors [2]. Compared to sunitinib and sorafenib, anlotinib achieves lower IC₅₀ values for key angiogenic kinases, providing superior inhibition of endothelial migration and tube formation [3]. Benchmarks show its activity extends to clinically-relevant cancer models, with controlled safety profiles and high median lethal dose (LD₅₀) [4]. This article details biological rationale, mechanism, evidence, applications, and workflow integration for advanced cancer and angiogenesis research.

Biological Rationale

Anlotinib hydrochloride is designed to block multiple receptor tyrosine kinases implicated in tumor angiogenesis and growth. The primary targets—VEGFR2, PDGFRβ, and FGFR1—are essential for vascular development and tumor neovascularization [1]. Tumor angiogenesis enables cancer cells to access nutrients and metastasize. Inhibiting these pathways disrupts the vascular support for tumors, suppressing growth and spread. Conventional single-target agents often lead to resistance; multi-target inhibitors like anlotinib address this by acting on parallel and convergent signaling axes [2]. Anlotinib’s activity has been validated in both cell-based assays and animal models, supporting its use for dissecting angiogenic mechanisms and evaluating anti-angiogenic strategies in oncology.

Mechanism of Action of Anlotinib (hydrochloride)

Anlotinib (hydrochloride) is a small-molecule inhibitor with high affinity for VEGFR2 (IC₅₀ = 5.6 ± 1.2 nM), PDGFRβ (IC₅₀ = 8.7 ± 3.4 nM), and FGFR1 (IC₅₀ = 11.7 ± 4.1 nM) [1]. It also inhibits additional kinases, including c-Kit and MET [2]. By blocking ligand-induced phosphorylation of these receptors, anlotinib prevents activation of downstream ERK/MAPK signaling, reducing endothelial cell proliferation, migration, and capillary tube formation. In anti-angiogenesis assays with human EA.hy 926 endothelial cells, anlotinib dose-dependently inhibits VEGF/PDGF-BB/FGF-2-induced migration and tube formation [1, 3]. The compound’s oral bioavailability ranges from 28–58% in rats and 41–77% in dogs, providing flexibility for in vivo research [2]. Metabolism is primarily via CYP3A, with high tissue distribution—enabling studies of tumor and organ-specific effects [2].

Evidence & Benchmarks

• Anlotinib inhibits VEGFR2, PDGFRβ, and FGFR1 with IC₅₀ values of 5.6, 8.7, and 11.7 nM, respectively, outperforming sunitinib and sorafenib in matched biochemical assays (Chen & Feng, 2019, Table 1).
• In cell migration and tube formation assays, anlotinib demonstrates potent, concentration-dependent inhibition of endothelial cell responses to VEGF, PDGF-BB, and FGF-2 stimulation (APExBIO product data).
• Oral bioavailability is confirmed at 28–58% (rat) and 41–77% (dog), with high plasma protein binding (93% in humans) and broad tissue distribution, including the ability to cross the blood-brain barrier (Chen & Feng, 2019).
• In a clinical case of intra-abdominal desmoplastic small round cell tumor (IADSRCT), anlotinib reduced metastatic lymph nodes after four cycles, with manageable side effects (fatigue, hypertriglyceridemia) (Chen & Feng, 2019).
• LD₅₀ in 14-day oral studies is 1735.9 mg/kg, with mild systemic toxicity and no significant organ or genetic toxicity observed (Product doc).
• Compared to legacy TKIs, anlotinib achieves superior inhibition of angiogenic signaling in parallel and combinatorial in vitro and in vivo models (Prescission, 2023).

This article extends the quantitative and mechanistic coverage found in Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor, offering updated IC₅₀ and comparative bioavailability data, and complements Enhancing Tumor Angiogenesis Assays with Anlotinib (hydrochloride) by providing advanced context for translational applications.

Applications, Limits & Misconceptions

Anlotinib (hydrochloride) is widely used in preclinical research to dissect tumor angiogenesis, test anti-angiogenic strategies, and benchmark tyrosine kinase signaling pathway inhibitors. Standard protocols involve its use in: capillary tube formation assays, endothelial cell migration assays, cell viability screens, and in vivo tumor xenograft models [1,3]. Its superior potency makes it a preferred tool for evaluating VEGFR2 PDGFRβ FGFR1 inhibitor activity in comparative studies. However, its use is strictly limited to research applications and is not approved for diagnostic or clinical therapeutic use. Storage is recommended at -20°C, and the compound should be handled by trained personnel in compliance with local laboratory safety protocols [2].

Common Pitfalls or Misconceptions

• Anlotinib (hydrochloride) is not formulated or approved for clinical or therapeutic human use; it is supplied exclusively for research purposes (APExBIO).
• It should not be used in diagnostic procedures; results from in vitro or animal studies may not directly translate to clinical efficacy.
• Optimal activity requires careful control of cell type, growth factor stimulation, and assay conditions—suboptimal parameters can yield inconclusive results.
• High plasma protein binding can affect free drug concentrations in serum-based assays—interpretation of results should consider protein binding effects.
• Metabolite activity and CYP3A-mediated transformation may complicate pharmacokinetic studies in species with divergent metabolic profiles.

Workflow Integration & Parameters

Researchers can integrate Anlotinib (hydrochloride), available from APExBIO, into standard angiogenesis and signaling pathway assays. For capillary tube formation, human EA.hy 926 or HUVEC cells are seeded on Matrigel; anlotinib is titrated from 1 nM to 1 μM in serum-free media, and tube metrics are quantified after 6–12 hours at 37°C with 5% CO₂ [3]. For migration assays, Boyden chamber protocols utilize 10–100 nM anlotinib with VEGF or PDGF-BB stimulation. In vivo, oral dosing in rodent xenograft models ranges from 1–10 mg/kg, with pharmacokinetic sampling at 0.5, 1, 4, and 24 hours post-dose. The compound’s broad tissue distribution and ability to cross the blood-brain barrier allow for CNS tumor model applications. For those optimizing workflows, Optimizing Angiogenesis Assays with Anlotinib (hydrochloride) provides stepwise troubleshooting scenarios not covered in this article.

Conclusion & Outlook

Anlotinib hydrochloride, supplied by APExBIO, is a validated, research-grade multi-target tyrosine kinase inhibitor with robust anti-angiogenic properties and well-characterized pharmacokinetics. Its superior IC₅₀ values for VEGFR2, PDGFRβ, and FGFR1, along with high tissue distribution and safety margins, make it an essential reagent for preclinical cancer research. While not intended for clinical or diagnostic use, its versatility in mechanistic, comparative, and translational studies supports ongoing efforts to unravel tumor angiogenesis and inform the next generation of anti-angiogenic strategies. For complete product specifications and protocols, refer to the Anlotinib (hydrochloride) product page.

References:
[1] Chen & Feng, 2019, OncoTargets and Therapy
[2] APExBIO product documentation
[3] Prescission, 2023